. The first of these new resources will be employed in France, with the specific objective of engaging medical systems offering clinical testing and screening services via a network of privately owned laboratories. We aim to approach several key laboratories to trial the EuGeni platform to create momentum for further roll-out. Additionally, we will be undertaking the required French clinical validation and aim to commence this in the coming weeks. We are also finalising similar approaches to align with market and regulatory requirements in Germany, UK, Italy and Spain
ADO Price at posting:
41.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)